8-K: Neurocrine Biosciences Q1 2026 Earnings & Soleno Acquisition

Neurocrine Biosciences reported a 44% year-over-year increase in Q1 2026 net product sales to $811 million, driven by INGREZZA and CRENESSITY, and announced a $2.9 billion acquisition of Soleno Therapeutics.

Summary

• Neurocrine Biosciences announced strong first-quarter 2026 financial results, with net product sales reaching $811.0 million, a 44% increase compared to the prior year.
• Total revenues for the quarter were $814.5 million, up 42% year-over-year.
• INGREZZA net sales were $656.9 million, a 20% increase year-over-year, attributed to strong patient demand.
• CRENESSITY net sales were $153.3 million, driven by robust patient demand and reimbursement.
• The company entered into a definitive agreement to acquire Soleno Therapeutics for $2.9 billion, which includes VYKAT XR for hyperphagia in Prader-Willi syndrome, expected to close in Q2 2026.
• A Phase 2 clinical study for NBI-1117570 in schizophrenia was initiated.
• Full-year 2026 INGREZZA net sales guidance was reaffirmed at $2.7 billion to $2.8 billion.

Sentiment

Score: 9

Explanation: StockSavvy.ai views this as a very positive filing, characterized by strong financial performance, strategic growth initiatives through acquisition, and a robust pipeline, indicating significant upside potential.

Positives

• Net product sales increased by 44% year-over-year to $811.0 million in Q1 2026.
• INGREZZA net sales grew 20% year-over-year to $656.9 million, with double-digit prescription volume growth.
• CRENESSITY net sales reached $153.3 million, demonstrating strong patient demand and reimbursement.
• Total revenues increased by 42% year-over-year to $814.5 million.
• GAAP net income significantly improved to $197.9 million from $7.9 million in the prior year.
• Non-GAAP net income also saw a substantial increase to $200.5 million from $71.5 million.
• The company reaffirmed its full-year 2026 INGREZZA net sales guidance of $2.7 billion to $2.8 billion.
• The acquisition of Soleno Therapeutics for $2.9 billion is expected to expand the company's portfolio and accelerate revenue growth.

Negatives

• While GAAP net income was $197.9 million, it included a $28.6 million pre-tax gain from the sale of Neurocrine Group Limited.
• GAAP R&D expenses increased to $296.2 million from $263.2 million, and GAAP SG&A expenses rose to $318.5 million from $276.5 million, reflecting investments in pipeline and commercialization.
• Acquired in-process R&D expense was $21.2 million in Q1 2026, compared to $0.1 million in Q1 2025.

Risks

• Risks associated with the proposed acquisition of Soleno Therapeutics, including the possibility that the transaction may not close or that anticipated benefits may not be realized.
• Potential for regulatory authorities to make adverse decisions regarding products or product candidates.
• Risks that development activities may not be initiated or completed on time, or may not be successful.
• Dependence on third parties for development, manufacturing, and commercialization activities.
• Competition from other therapies or products, including potential generic entrants.
• Government and third-party regulatory and policy efforts that may impose sales and pharmaceutical pricing controls or limit coverage and reimbursement.
• The possibility that the expected benefits from the Soleno acquisition will not be realized or will not be realized within the expected time period.
• Integration of Soleno Therapeutics business may be more difficult, time-consuming, or costly than expected.

Future Outlook

The company reaffirmed its full-year 2026 INGREZZA net sales guidance of $2.7 billion to $2.8 billion. The acquisition of Soleno Therapeutics is expected to close in Q2 2026 and contribute to future revenue growth. The pipeline includes multiple compounds in mid- to late-phase clinical development.

Management Comments

• Neurocrines strong first-quarter performance reflects continued momentum across our commercial portfolio, as we advance our growth strategy and diversify across therapeutic areas.
• We delivered $811 million in net product sales, representing 44% year-over-year growth, driven by continued strong demand for INGREZZA and CRENESSITY.
• Our recently announced agreement to acquire Soleno Therapeutics further underscores our commitment to address conditions with significant unmet need and accelerate revenue growth.
• With multiple first-in-class commercial medicines and the deepest pipeline in our history, Neurocrine is well-positioned to deliver transformative therapies for patients and drive sustained growth.

Industry Context

StockSavvy.ai notes that Neurocrine Biosciences' strong Q1 2026 results and strategic acquisition of Soleno Therapeutics align with industry trends of consolidation and focus on rare diseases and specialized therapeutic areas. The company's growth in net product sales, particularly for INGREZZA, demonstrates effective commercial execution in competitive markets.

Management Changes

Stakeholder Impact

• Shareholders: Potential for increased shareholder value due to strong financial performance, strategic acquisition, and pipeline advancements.
• Employees: Expansion of the company's operations and leadership roles may create new opportunities.
• Patients: Continued access to and development of treatments for neuropsychiatric, neurological, endocrine, and immunological disorders, including new potential therapies for Prader-Willi syndrome and schizophrenia.
• Healthcare Providers: Continued availability of effective treatments like INGREZZA and CRENESSITY, with new data supporting their use.

Next Steps

• Complete the acquisition of Soleno Therapeutics in Q2 2026.
• Continue advancing the Phase 2 clinical study of NBI-1117570 in adults with schizophrenia.
• Evaluate the safety and tolerability of NBIP-2118 in the Phase 1 study.
• Continue commercialization efforts for INGREZZA and CRENESSITY.
• Monitor progress of ongoing clinical development programs, including Phase 3 studies for osavampator and direclidine.

Key Dates

Recommendation

The company demonstrated exceptional Q1 2026 financial results with significant year-over-year growth in net product sales and profitability. The strategic acquisition of Soleno Therapeutics, coupled with a strong pipeline and reaffirmed full-year guidance, positions Neurocrine Biosciences for sustained growth and market leadership. These factors strongly suggest a positive trajectory for the stock.

Keywords

Neurocrine Biosciences, NBIX, Q1 2026 Earnings, INGREZZA, CRENESSITY, Soleno Therapeutics Acquisition, VYKAT XR, Prader-Willi Syndrome